Eye-position signals in successive saccades

H. Honda

DOI: https://doi.org/10.3758/BF03206349

Perception & Psychophysics

Abstract:

What problem does this paper attempt to address?

Ruthenium(II) Complexes with 2-Phenylimidazo[4,5-f][1,10]phenanthroline Derivatives that Strongly Combat Cisplatin-Resistant Tumor Cells

Leli Zeng,Yu Chen,Jiangping Liu,Huaiyi Huang,Ruilin Guan,Liangnian Ji,Hui Chao

DOI: https://doi.org/10.1038/srep19449

IF: 4.6

2016-01-14

Scientific Reports

Abstract:AbstractCisplatin was the first metal-based therapeutic agent approved for the treatment of human cancers, but its clinical activity is greatly limited by tumor drug resistance. This work utilized the parent complex [Ru(phen)2(PIP)]2+ (1) to develop three Ru(II) complexes (2–4) with different positional modifications. These compounds exhibited similar or superior cytotoxicities compared to cisplatin in HeLa, A549 and multidrug-resistant (A549R) tumor cell lines. Complex 4, the most potent member of the series, was highly active against A549R cancer cells (IC50 = 0.8 μM). This complex exhibited 178-fold better activity than cisplatin (IC50 = 142.5 μM) in A549R cells. 3D multicellular A549R tumor spheroids were also used to confirm the high proliferative and cytotoxic activity of complex 4. Complex 4 had the greatest cellular uptake and had a tendency to accumulate in the mitochondria of A549R cells. Further mechanistic studies showed that complex 4 induced A549R cell apoptosis via inhibition of thioredoxin reductase (TrxR), elevated intracellular ROS levels, mitochondrial dysfunction and cell cycle arrest, making it an outstanding candidate for overcoming cisplatin resistance.

multidisciplinary sciences
Ruthenium(II) complexes as mitochondrial inhibitors of topoisomerase induced A549 cell apoptosis

Hong Tang,Xinhua Guo,Wenzhu Yu,Jie Gao,Xufeng Zhu,Zunnan Huang,Wenhui Ou,Hanfu Zhang,Lanmei Chen,Jincan Chen

DOI: https://doi.org/10.1016/j.jinorgbio.2023.112295

IF: 4.336

2023-06-16

Journal of Inorganic Biochemistry

Abstract:Two new ruthenium(II) complexes [Ru(dip) 2 (PPβC)]PF 6 (Ru1, dip = 4,7-diphenyl-1,10-phenanthroline, PPβC = N-(1,10-phenanthrolin-5-yl)-1-phenyl-9H-pyrido[3,4- b ]indole-3-carboxamide) and [Ru(phen) 2 (PPβC)]PF 6 (Ru2, phen = 1, 10-phenanthroline) with β-carboline derivative PPβC as the primary ligand, were designed and synthesized. Ru1 and Ru2 displayed higher antiproliferative activity than cisplatin against the test cancer cells, with IC 50 values ranging from 0.5 to 3.6 μM. Moreover, Ru1 and Ru2 preferentially accumulated in mitochondria and caused a series of changes in mitochondrial events, including the depolarization of mitochondrial membrane potential, the damage of mitochondrial DNA, the depletion of cellular ATP, and the elevation of intracellular reactive oxygen species levels. Then, it induced caspase-3/7-mediated A549 cell apoptosis. More importantly, both complexes could act as topoisomerase I catalytic inhibitors to inhibit mitochondrial DNA synthesis. Accordingly, the developed Ru(II) complexes hold great potential to be developed as novel therapeutics for cancer treatment.

biochemistry & molecular biology,chemistry, inorganic & nuclear
Increasing the cytotoxicity of Ru(II) polypyridyl complexes by tuning the electron donating ability of 1,10-phenanthroline ligands

Yang Lu,Zhiying Hou,Mengshan Li,Ning Wang,Jinhui Wang,Feng Ni,Yufen Zhao,Bin Zhang,Ning Xi

DOI: https://doi.org/10.1039/d2dt02332f

IF: 4

2022-10-01

Dalton Transactions

Abstract:Ruthenium (Ru)-based chemotherapeutic agents are a choice to replace traditional platinum-containing metallodrugs due to the fewer side effects. It has been proved that the mechanism for Ru complex drugs is highly likely to bind with DNA and certain proteins, which also highly depend on the electronic structures of Ru complexes. However, systemically investigation of the relationship between electronic properties and chemotherapeutic activities has not been fully understood, which limits the effective drug design strategies. Here, we proposed that increasing the electron densities of Ru would enhance the nucleophilic substitution rate of chlorine atom (Cl) on Ru, providing better bioactivity against both amino acids and nucleic acids. A series of complexes with various optimized electron-donating groups (EDGs) were synthesized according to the DFT calculation. And kinetics substitution with L-histidine, DNA binding experiments, and cell cytotoxicity studies verified our assumptions. Surprisingly, these complexes could also be potential cellular imaging probes via an unprecedented "off-on" light switching mechanism of living cells, which was caused by "HOMO-LUMO" distribution changes of Ru complexes after the interaction with DNA. Accordingly, the reactivity and selectivity demonstrated by these compounds support the further development of these Ru complexes in cancer treatments and afford strategic perspectives on the development of metal complexes chemotherapeutic agents and bioimaging probes.

chemistry, inorganic & nuclear
Systematic evaluation of the antitumor activity of three ruthenium polypyridyl complexes

Guang-Bin Jiang,Wen-Yao Zhang,Miao He,Yi-Ying Gu,Lan Bai,Yang-Jie Wang,Qiao-Yan Yi,Fan Du

DOI: https://doi.org/10.1016/j.jinorgbio.2021.111616

IF: 4.336

2021-12-01

Journal of Inorganic Biochemistry

Abstract:Ruthenium-containing complexes have emerged as good alternative to the currently used platinum-containing drugs for malignant tumor therapy. In this work, cytotoxic effects of recently synthesized ruthenium polypyridyl complexes [Ru(bpy)2(CFPIP)](ClO4)2 (bpy = 2,2′-bipyridine, CFPIP = (E)-2-(4-fluorostyryl)-1H-imidazo[4,5-f][1,10]phenanthroline, Ru(II)-1), [Ru(phen)2(CFPIP)](ClO4)2 (phen = 1,10-phenanthroline, Ru(II)-2) and [Ru(dmb)2(CFPIP)](ClO4)2 (dmb = 4,4′-dimethyl-2,2′-bipyridine, Ru(II)-3) toward different tumor cells were investigated in vitro and compared with cisplatin, the most widely used chemotherapeutic drug against hepatocellular carcinoma (HepG-2). The results demonstrate that target complexes show excellent cytotoxicity against HepG-2 cells with low IC50 value of 21.4 ± 1.5, 18.0 ± 2.1 and 22.3 ± 1.7 μM, respectively. It was important noting that target Ru(II) complexes exhibited better antitumor activity than cisplatin (IC50 = 28.5 ± 2.4 μM) against HepG-2 cells, and has no obvious toxicity to normal cell LO2. DNA binding results suggest that Ru(II)-1, Ru(II)-2 and Ru(II)-3 interact with CT DNA (calf thymus DNA) through intercalative mode. Complexes exerted its antitumor activity through increasing anti-migration and inducing cell cycle arrest at the S phase. In addition, the apoptosis was tested by AO (acridine orange)/EB (ethidium bromide) staining and flow cytometry. Mitochondrial membrane potential (MMP), reactive oxygen species (ROS), and colocalization tests were also evaluated by ImageXpress Micro XLS system. Overall, the results show that the ruthenium polypyridyl complexes induce apoptosis in HepG-2 cells through ROS-mediated mitochondria dysfunction pathway.

biochemistry & molecular biology,chemistry, inorganic & nuclear
Homo and heterometallic ruthenium and platinum complexes with multiple targets for therapeutic applications: a review

Senjuti De,Samik Nag

DOI: https://doi.org/10.1515/revic-2023-0007

2023-05-11

Reviews in Inorganic Chemistry

Abstract:We are now well-positioned to comprehend carcinogenesis at a molecular level in greater detail due to significant technological advancements. Additionally, we are now able to rationally design and develop drug molecules with the ability to either selectively enhance or disrupt important biological processes, maximizing their therapeutic potential. This has heralded a new era in drug design. The heterometallic ruthenium–platinum complexes can be used as anticancer, photodynamic therapy, diabetes treatment, and molecular sensors for thiol-containing peptides due to their multifunctional interactions with nuclear DNA, mitochondrial DNA, RNA, and proteins. Compared to cisplatin and its Ru-based monometallic precursors, a significant number of reported ruthenium–platinum complexes exhibit enhanced cytotoxicity and tumor selectivity. Due to the covalent binding of the cis-Pt II Cl 2 moiety to DNA, photoactive Ru(II)–Pt(II) complexes were designed to prelocalize a photodynamic therapy agent at the site of action. The development of ruthenium–platinum-based heterometallic complexes has recently advanced, opening up new avenues for the development of drugs that are more efficient. Metal complexes' potential as important cancer therapeutic agents will be the primary focus of this review. The development of ruthenium and platinum-based mono and mixed-metal complexes with therapeutic and biomedical applications are discussed in detail in this article.

chemistry, inorganic & nuclear
Antitumor studies evaluation of triphenylphosphine ruthenium complexes with 5,7-dihalo-substituted-8-quinolinoline targeting mitophagy pathways

Zhen-Feng Wang,Xiao-Qiong Huang,Run-Chun Wu,Yu Xiao,Shu-Hua Zhang

DOI: https://doi.org/10.1016/j.jinorgbio.2023.112361

IF: 4.336

2023-11-01

Journal of Inorganic Biochemistry

Abstract:Both ruthenium-containing complexes and 8-quinolinoline compounds have emerged as a potential novel agent for malignant tumor therapy. Here, three triphenylphosphine ruthenium complexes, [Ru(ZW1)(PPh3)2Cl2] (PPh3 = triphenylphosphine) (RuZ1), [Ru(ZW2)(PPh3)2Cl2] (RuZ2) and [Ru(ZW2)2(PPh3)Cl2]·CH2Cl2 (RuZ3) bearing 5,7-dichloro-8-quinolinol (H-ZW1) and 5,7-dichloro-8-hydroxyquinaldine (H-ZW2), have been synthesized, characterized and tested for their anticancer potential. We showed that triphenylphosphine ruthenium complexes RuZ1-RuZ3 impaired the cell viability of ovarian adenocarcinoma cisplatin-resistant SK-OV-3/DDP (SKO3CR) and SK-OV-3 (SKO3) cancer cells with greater selectivity and specificity than cisplatin. In addition, RuZ1-RuZ3 show higher excellent cytotoxicity than cisplatin towards SKO3CR cells, with IC50 values of 9.66 ± 1.08, 4.05 ± 0.67 and 7.18 ± 0.40 μM, respectively, in which the SKO3CR cells was the most sensitive to RuZ1-RuZ3. Depending on the substituent type, the antiproliferative ability of RuZ1-RuZ3 followed the trend: -CH3 > -H. However, RuZ1-RuZ3 have no obvious toxicity to normal cell HL-7702. Besides, RuZ1 and RuZ2 could induce mitophagy related-apoptosis pathways through suppression of mitochondrial membrane potential (ΔΨm), accumulation of [Ca2+] and reactive oxygen species (ROS), and regulation of LC3 II/LC3 I, Beclin-1, P62, FUNDC1, PINK1, Parkin, cleaved-caspase-3, caspase-9 and cytochrome c signaling pathway, and hindering the preparation of mitochondrial respiration complexes I and IV and ATP levels. Mechanistic study revealed that RuZ1 and RuZ2 induce apoptosis in SKO3CR cells via mitophagy related-apoptosis pathways induction and energy (ATP) generation disturbance. Taken together, the studied triphenylphosphine ruthenium complexes RuZ1-RuZ3 are promising chemotherapeutic agents with high effectiveness and low toxicity.

biochemistry & molecular biology,chemistry, inorganic & nuclear
Exploring the potential of ruthenium(ii)–phosphine–mercapto complexes as new anticancer agents

Marcos V. Palmeira-Mello,Analu R. Costa,Leticia P. de Oliveira,Olivier Blacque,Gilles Gasser,Alzir A. Batista

DOI: https://doi.org/10.1039/d4dt01191k

IF: 4

2024-06-20

Dalton Transactions

Abstract:The search for new metal-based anticancer drug candidates is a fundamental task in medicinal inorganic chemistry. In this work, we assessed the potential of two new Ru( II )–phosphine–mercapto complexes as potential anticancer agents. The complexes, with the formula [Ru(bipy)(dppen)(Lx)]PF 6 [( 1 ), HL1 = 2-mercapto–pyridine and ( 2 ), HL2 = 2-mercapto–pyrimidine, bipy = 2,2′-bipyridine, dppen = cis -1,2-bis(diphenylphosphino)-ethylene] were synthesized and characterized by nuclear magnetic resonance (NMR) [ 1 H, 31 P( 1 H), and 13 C], high resolution mass spectrometry (HR-MS), cyclic voltammetry, infrared and UV-Vis spectroscopies. Complex 2 was obtained as a mixture of two isomers, 2a and 2b , respectively. The composition of these metal complexes was confirmed by elemental analysis and liquid chromatography-mass spectrometry (LC-MS). To obtain insights into their lipophilicity, their distribution coefficients between n -octanol/PBS were determined. Both complexes showed affinity mainly for the organic phase, presenting positive log P values. Also, their stability was confirmed over 48 h in different media ( i.e. , DMSO, PBS and cell culture medium) via HPLC, UV-Vis and 31 P{ 1 H} NMR spectroscopies. Since enzymes from the P-450 system play a crucial role in cellular detoxification and metabolism, the microsomal stability of 1 , which was found to be the most interesting compound of this study, was investigated using human microsomes to verify its potential oxidation in the liver. The analyses by LC-MS and ESI-MS reveal three main metabolites, obtained by oxidation in the dppen and bipy moieties. Moreover, 1 was able to interact with human serum albumin (HSA). The cytotoxicity of the metal complexes was tested in different cancerous and non-cancerous cell lines. Complex 1 was found to be more selective than cisplatin against MDA-MB-231 breast cancer cells when compared to MCF-10A non-cancerous cells. In addition, complex 1 affects cell morphology and migration, and inhibits colony formation in MDA-MB-231 cells, making it a promising cytotoxic agent against breast cancer.

chemistry, inorganic & nuclear
Photoinduced synergistic cytotoxicity towards cancer cells via Ru(II) complexes

Zhong Han,Yuncong Chen,Yanjun Wang,Xiangchao Shi,Hao Yuan,Yang Bai,Zhongyan Chen,Hongbao Fang,Weijiang He,Zijian Guo

DOI: https://doi.org/10.1039/d0dt02627a

IF: 4

2020-01-01

Dalton Transactions

Abstract:Ru(II) complexes have been recognized as excellent anticancer candidates. However, the poor cell uptake of these complexes has been the major obstacle in improving their anticancer efficacy. Along with the development of the knowledge on the anticancer nature of the Ru(II) complexes, several strategies have been designed to increase the cellular accumulation of these complexes. Among them, the light-triggered drug uptake approach is most promising. In this study, a bioactive Ru(II)-polypyridyl complex Ru-1 is constructed via incorporating a modified phenanthroline ligand into the enlarged conjugate structure. The modulation of the ligand makes Ru-1 powerful in generating singlet oxygen and effective in photodynamic therapeutic activity. Moreover, the cell uptake is improved during this photodynamic process and induces further chemotherapeutic effect, which act synergistically to enhance its anticancer activity. The photoinduced synergistic cytotoxicity of Ru-1 towards cancer cells offers an effective way to sensitize the antitumor activity of Ru(II) complexes.
A Comparative Study on Interactions of Cisplatin and Ruthenium Arene Anticancer Complexes with Metallothionein Using MALDI-TOF-MS

Guangxue Zhang,Wenbing Hu,Zhifeng Du,Shuang Lv,Wei Zheng,Qun Luo,Xianchan Li,Kui Wu,Yumiao Han,Fuyi Wang

DOI: https://doi.org/10.1016/j.ijms.2010.12.003

IF: 1.934

2011-01-01

International Journal of Mass Spectrometry

Abstract:Metallothioneins (MTs) are a group of low molecular weight (6–7KDa) proteins featured by high cysteine content which allows the proteins to bind to a diverse range of metals. MTs, of which the gene transcription can be induced by a variety of stimuli including hormones, cytokines and metal ions, have important biological functions such as storage, trafficking and homeostasis of metal ions, detoxification of heavy metals, resistance to ionizing radiation, scavenging hydroxyl radical, etc. Importantly, it has been reported that MTs play a role in oncogenesis and cancer prognosis, and are implicated in resistance of cancer cells to anticancer metallodrug cisplatin. In this work, we present a comparative study on interactions between MTs and cisplatin and ruthenium arene anticancer complexes using MALDI-TOF-MS. The results show that cisplatin coordinates to MT-I and MT-II at either pH 3.0 or 7.4, and exhibits a higher affinity to MT-II than to MT-I. The MT–Pt complexes increase significantly in content with decrease in pH values of solutions, indicative that cisplatin competes with zinc for coordination to cysteine residues on MTs and interferes with the binding of zinc to the proteins. While the ruthenium arene anticancer complexes [(η6-arene)Ru(en)Cl]PF6 (arene=benzene or biphenyl, en=ethylenediamine) hardly bind to MTs at acidic pH and coordinate to MTs at a much lower level than cisplatin at neutral pH, which may account for the less toxicity and lack of cross-resistance to cisplatin for this class of ruthenium anticancer complexes. With the MT–Pt complexes as model protein complexes, DDT, the widely used unfolding thiol-containing agent in proteomic research was shown to reduce the coordination of platinum to MTs significantly, implying that DDT used as unfolding reagent at high concentration may cause dissociation of bound metallodrug and should be applied with care.
Design, synthesis and anticancer evaluation of novel half-sandwich Ru(II) complexes bearing pyrazalone moiety: Apoptosis inducers based on mitochondrial dysfunction and G0/G1 arrest

Yunhou Huang,Shaoling Huang,Wanxing Wei,Yanchun Wu,Limei Jia,Yijia Du,Peng Luo,Weigao Pan

DOI: https://doi.org/10.1016/j.jinorgbio.2023.112421

IF: 4.336

2024-01-01

Journal of Inorganic Biochemistry

Abstract:Six half-sandwich Ru(II) complexes (Ru1-Ru6), integrated with 5-phenyl-2-(pyridin-2-yl)-2,4-dihydro-3H-pyrazol-3-one (PDPO1-PDPO6) ligands, were synthesized and spectroscopically characterized. The structure of Ru3 that crystallized as a monoclinic crystal with P21/c space group was further confirmed by X-ray single crystal diffraction. Prototropic tautomerism within the complexes transformed OH-form ligands to NH-form, forming a hydrogen bond (Cl1---H-N3). The complexes and ligands' cytotoxicity was assessed against several cancerous (HepG2, A549, MCF-7) and normal Vero cell lines. Relative to the ligands and Cisplatin, complexes (Ru2, Ru3, Ru5, Ru6) exhibited potent cytotoxicity against cancer cells, with IC50 values from 2.05 to 15.69 μM/L, excluding Ru1 and Ru4. Specifically, Ru2, Ru3, and Ru5 demonstrated superior anti-HepG2 properties. Compared to Cisplatin, Ru2 and Ru5 were less toxic to Vero cells, highlighting their enhanced selectivity in toxicity. Structure-activity relationship (SAR) studies indicated that t-butyl substitution (in Ru2) or -Cl (in Ru5) on the benzene ring significantly improved the selective toxicity. These complexes manifested substantial lipophilicity, cellular uptake, and were quickly hydrolyzed to Ru-H2O species. Roughly positive correlations were observed between hydrolysis rate, lipophilicity, cellular uptake, and anticancer activities. Ru2, investigated specifically, induced apoptosis in HepG2 cells at concentrations of 10 and 20 μM/L through ROS-mediated mitochondrial dysfunction and G0/G1phase arrest, associated with altered P21, cyclin D, and CDK4 expression levels.

biochemistry & molecular biology,chemistry, inorganic & nuclear
Cyclometalated Ru(II)-NHC Complexes with Phenanthroline Ligand Induce Apoptosis Mediated by Mitochondria and Endoplasmic Reticulum Stress in Cancer Cells

Chao Chen,He Lv,Hao Xu,Dancheng Zhu,Chao Shen

DOI: https://doi.org/10.1039/d2dt03405k

IF: 4

2022-12-27

Dalton Transactions

Abstract:The exploration of ruthenium complexes as anticancer drugs has been the focus of intense investigation. In this study, we synthesized and characterized four C,N-cyclometalated ruthenium(II) complexes (Ru1-Ru4) coordinated with pyridine-functionalized N-heterocyclic carbene (NHC) and auxiliary ligands (e.g., acetonitrile, 1,10-phenanthroline, 3,4,7,8-tetramethyl-1,10-phenanthroline, and 4,7-diphenyl-1,10-phenanthroline). X-ray diffraction analysis showed that all of the four cycloruthenated complexes are hexa-coordinated in a typical octahedral geometry. In vitro cytotoxic studies revealed that cyclometalated Ru-NHC complexes Ru3 and Ru4 had stronger anticancer activity than their corresponding Ru-NHC precursor Ru1 and the clinically used cisplatin. For HeLa cells, Ru3 and Ru4 presented potent cytotoxicity with the IC50 value of 4.31 ± 0.42 μM and 3.14 ± 0.23 μM, which was approximately three times lower than that of cisplatin. More interestingly, Ru3 and Ru4 not only effectively inhibited the proliferation of HeLa cells, but also exhibited potential anti-migration activity. In the scratch wound healing assay, Ru3 and Ru4 treatment significantly reduced the wound healing rate of HUVEC cells. Mechanistic studies showed that Ru3 and Ru4 caused a dual action mode of mitochondrial membrane depolarization and endoplasmic reticulum stress, and finally induced the apoptosis of HeLa cells.

chemistry, inorganic & nuclear
Frequent activation of c-kis as a transforming gene in fibrosarcomas induced by methylcholanthrene.

A. Eva,S. Aaronson

DOI: https://doi.org/10.1126/SCIENCE.6302839

IF: 56.9

1983-05-27

Science

Abstract:The DNA's from two of four methylcholanthrene-induced mouse fibrosarcomas contained transforming genes that were identical in their pattern of restriction endonuclease resistance to inactivation of biologic activity. This transforming gene was identified as the activated homolog of the Kirsten murine sarcoma virus onc gene, v-kis. The finding that a defined carcinogen reproducibly leads to activation of kis as a transforming gene should be of value in elucidating the role of oncogenes in the neoplastic process.
The ruthenium complex assists in nuclear targeting and selective killing of tumor cells

Yu Lu,Di Zhu,Liujia Chan,Bo Hu,MarMar Tuohan,Li Li,Wei Wang,Yuji Wang

DOI: https://doi.org/10.1039/d3nr02707d

IF: 6.7

2023-06-20

Nanoscale

Abstract:In clinical studies, the toxicity of platinum-based antitumor drugs limits their use. DNA is the most widely studied target of metal-based complexes. Thus, nuclear targeting and selective killing have become the purpose of ruthenium complex design. We synthesized a carboline derivative and its ruthenium complex, NBD and NBD-Ru, and characterized their properties. UV spectra were used to monitor their stability. Transmission electron microscopy and dynamic light scattering were used to identify the self-assembly properties. Inductively coupled plasma mass spectrometry was used to assay the distribution of the Ru complexes in cells with or without transferrin. Besides, the tumor cell killing activities with or without transferrin were detected by MTT assay. An imaging flow cytometer was applied to observe the fluorescence further to identify the cellular distribution. The effects of NBD and NBD-Ru on DNA and the cell cycle were also measured. In vivo, the antitumor and antimetastatic activities of NBD and NBD-Ru were assessed in S180 and LLC tumor-bearing mice. We found that introducing Ru improved the solubility and stability, enabling NBD-Ru to self-assemble into nanoparticles with the EPR effect. At the same time, binding affinity with transferrin increased significantly after complexation, allowing NBD-Ru could target and selectively kill tumors via Tf/TfR pathway. More interestingly, ruthenium assisted the complex in achieving nuclear penetration, which can kill tumor cells by interacting with DNA. In vivo experiments further verified our conclusion in vitro. NBD-Ru could inhibit not only the growth of a primary tumor but also lung metastasis, which was related to the killing effect of the complex on tumor cells (ki67) and inhibition of neovascularization (CD31). At the same time, the systemic toxicity of the ruthenium complex in vivo was reduced because of the targeting effect, and the biosafety was improved. In conclusion, we found that ruthenium assisted in nuclear targeting and selective killing in vitro and in vivo.

materials science, multidisciplinary,physics, applied,nanoscience & nanotechnology,chemistry
Multi-targeted organometallic ruthenium(II)-arene anticancer complexes bearing inhibitors of poly(ADP-ribose) polymerase-1: A strategy to improve cytotoxicity.

Zhigang Wang,Hui Qian,Shek-Man Yiu,Jianwei Sun,Guangyu Zhu

DOI: https://doi.org/10.1016/j.jinorgbio.2013.10.017

IF: 4.336

2014-01-01

Journal of Inorganic Biochemistry

Abstract:Small-molecule inhibitors of poly(ADP-ribose) polymerase-1 (PARP-1) have currently drawn much attention as promising chemotherapeutic drug candidates, and there is a need to develop more potent PARP inhibitors with improved bioavailability. Here we report a strategy to improve the cytotoxicity of PARP inhibitors by conjugation with organometallic ruthenium(II)–arene compounds. We also report a systematic study to reveal the mechanism of action of these ruthenium–PARP inhibitor conjugates. The complexes have been synthesized and characterized spectroscopically. The improved antiproliferative activity from the as-prepared complexes in four human cancer cell lines has indicated their potential for further development as antitumor drugs. Cellular uptake study reveals that the most active complex 3 easily entered into cells. Target validation assays show that the complexes inhibited PARP-1 slightly better than the original PARP inhibitors, that complex 3 strongly bound to DNA and inhibited transcription, and that this complex arrested the cell cycle at the G0/G1 stage. This type of information could shed light on the design of the next generation of more active ruthenium–PARP inhibitor conjugates.
Ru(ii) polypyridyl complex-incorporated and folate-conjugated vehicle for cancer cell imaging and photoinduced inactivation.

Li-Li Huang,Jin Xu,Yong-Jie Jin,Dong-Xu Zhao,Hai-Yan Xie

DOI: https://doi.org/10.1039/c5an02650d

2016-01-01

Abstract:Ru(II) polypyridyl complexes have been expected as promising therapeutic agents against cancer owing to its DNA photocleavage activity. However, the lack of cell selectivity poses a significant obstacle to their practical application. Herein, the strategy combining cell-specific imaging with photoinduced cell death based on [Ru(phen)(2)(dppz)](2+) has been developed by incorporating [Ru(phen)(2)(dppz)](2+) into folate-conjugated liposomes. The cells overexpressing folate receptors could specifically recognize this vehicle and be imaged through the luminescence of [Ru(phen)(2)(dppz)](2+). Thereafter, the delivered [Ru(phen)(2)(dppz)](2+) interacted with DNA in cells and led to photoinduced cell death. This work provided a possible alternative for cancer diagnosis and therapy.
Biotin-conjugated Ru(II) complexes with AIE characteristics as mitochondria-targeted photosensitizers for enhancing photodynamic therapy by disrupting cellular redox balance

Lai Wei,Xiangdong He,Deming Zhao,Martha Kandawa-Shultz,Guoqiang Shao,Yihong Wang

DOI: https://doi.org/10.1016/j.ejmech.2023.115985

IF: 7.088

2024-01-01

European Journal of Medicinal Chemistry

Abstract:The potential use of Ru(II) complexes as photosensitizers (PSs) in photodynamic therapy (PDT) has gained significant attention. In comparison with fluorophores with aggregation-caused quenching (ACQ), fluorophores with aggregation-induced emission (AIE) characteristics exhibit sustained fluorescence and dispersibility in aqueous solutions. PSs with AIE characteristics have received much attention in recent years. Herein, we reported two novel biotin-conjugated Ru(II) polypyridyl complexes (Ru1 and Ru2) with AIE characteristics. When exposed to 460 nm (10 mW cm-2) light, Ru1 and Ru2 exhibited outstanding photostability and photocatalytic activity. Ru1 and Ru2 could efficiently generate singlet oxygen and induce pUC19 DNA photolysis when exposed to 460 nm light. Interestingly, both Ru1 and Ru2 also functioned as catalysts for NADH oxidation when exposed to 460 nm light. The presence of biotin fragments in Ru1 and Ru2 enhanced the specific uptake of these complexes by tumor cells. Both complexes showed minimal toxicity to selected cells in the dark. Nevertheless, the phototoxicity of both complexes significantly increased upon 460 nm light irradiation for 15 min. Further experiments revealed that Ru2 primarily accumulated in mitochondria and might bind to mitochondrial DNA. Under 460 nm light irradiation, Ru2 induced the generation of reactive oxygen species (ROS) and NADH depletion disrupting intracellular redox homeostasis in A549 cells, activating the mitochondrial apoptosis pathway resulting in up-regulation of apoptotic marker caspase-3, effectively damaged A549 cell DNA and arrested A549 cell cycle in the S phase. In vivo anti-tumor experiments were conducted to assess the effects of Ru2 on tumor growth in A549 tumor-bearing mice. The results showed that Ru2 effectively inhibited tumor growth under 460 nm light irradiation conditions. These findings indicate that Ru2 has great potential as a targeted photosensitizer for mitochondrial targeting imaging and photodynamic therapy of tumors.

chemistry, medicinal
Ruthenium Complexes as Promising Candidates against Lung Cancer

Qi Sun,Yingsi Li,Hongdong Shi,Yi Wang,Jitian Zhang,Qianling Zhang

DOI: https://doi.org/10.3390/molecules26154389

IF: 4.6

2021-07-21

Molecules

Abstract:Lung cancer is one of the most common malignancies with the highest mortality rate and the second-highest incidence rate after breast cancer, posing a serious threat to human health. The accidental discovery of the antitumor properties of cisplatin in the early 1960s aroused a growing interest in metal-based compounds for cancer treatment. However, the clinical application of cisplatin is limited by serious side effects and drug resistance. Therefore, other transition metal complexes have been developed for the treatment of different malignant cancers. Among them, Ru(II/III)-based complexes have emerged as promising anticancer drug candidates due to their potential anticancer properties and selective cytotoxic activity. In this review, we summarized the latest developments of Ru(II/III) complexes against lung cancer, focusing mainly on the mechanisms of their biological activities, including induction of apoptosis, necroptosis, autophagy, cell cycle arrest, inhibition of cell proliferation, and invasion and metastasis of lung cancer cells.

chemistry, multidisciplinary,biochemistry & molecular biology
A lysosome-targeted ruthenium(II) polypyridyl complex as photodynamic anticancer agent

Jun Chen,Qin Tao,Jian Wu,Mengmeng Wang,Zhi Su,Yong Qian,Tao Yu,Yan Wang,Xuling Xue,Hong-Ke Liu

DOI: https://doi.org/10.1016/j.jinorgbio.2020.111132

IF: 4.336

2020-09-01

Journal of Inorganic Biochemistry

Abstract:Polypyridyl ruthenium complexes as novel photosensitizers had drawn attention due to its high selectivity towards cancer cells and low toxicity to normal cells. Herein, we synthesized a lysosome-targeted polypyridyl ruthenium complex Rhein-Ru(bpy)3 (bpy = 2,2′-bipyridine, rhein = 4,5-dihydroxy-9,10-dioxoanthracene-2-carboxylic acid), tethering with the Chinese medicine herb rhein. Rhein-Ru(bpy)3 exhibited high phototoxicity with short time of irradiation against tumor cell lines with the IC50 value of 2.4– 8.7 μM, and higher cytotoxicity against cisplatin-resistant A2780 cell lines, suggesting that Rhein-Ru(bpy)3 could overcome the cisplatin resistance. Moreover, Rhein-Ru(bpy)3 displayed low cytotoxicity towards cell lines in dark incubation, which was beneficial to reduce the toxic side effects towards normal cell lines. Besides, the confocal imaging and western blotting assay results suggested that Rhein-Ru(bpy)3 could induce cancer cell death through the autophagy pathway. These results inspired us that lysosome-targeted photosensitizers based on ruthenium complexes showed great potential for photodynamic therapy (PDT) application in cancer treatment.

biochemistry & molecular biology,chemistry, inorganic & nuclear
Photocytotoxic Kinetically Stable Ruthenium(II)-N,N-donor Polypyridyl Complexes of Oxalate for Anticancer Activity Against HepG2 Liver Cancer Cells

Juhi Sayala,Ekta Srivastava,Priyaranjan Kumar,Nitin Shukla,Ashok Kumar,Ashis Kumar Patra

DOI: https://doi.org/10.1039/d3dt04058e

IF: 4

2024-01-30

Dalton Transactions

Abstract:Liver cancer is one of the leading causes of death motivating scientists worldwide to synthesize novel therapeutics. Ru(II)-polypyridyl complexes are extensively studied for possible therapeutic and cellular applications due to their tunable coordination chemistry, structural diversity, ligand-exchange kinetics, accessible redox states, and rich photophysical or photochemical properties. Herein, we have synthesized a series of Ru(II) polypyridyl complexes [RuII(N^N) 2 (ox)] ( 1 - 3 ), where ox is oxalate (C2O42-), N^N is 1,10-phenanthroline (phen) ( 1 ), dipyrido[3,2-d:2',3'-f]quinoxaline (dpq) ( 2 ), and dipyrido[3,2,-a:2',3'-c]phenazine (dppz) ( 3 ). The oxalate (ox 2- ) was opted as a bioactive dioxo ligand to prevent hydrolysis in aqueous media, thereby increasing the stability of the Ru(II)-polypyridyl complexes in physiological media. We thoroughly characterized all the complexes using ESI-MS, FT-IR, UV-vis, and 1H NMR spectroscopy and other physicochemical methods. The complexes were stable under physiological conditions and under low-energy green LED light (λirr= 530 nm). However, the photoirradiation of complexes resulted in the efficient generation of singlet oxygen ( 1 O 2 ) as a major reactive oxygen species (ROS). The role of extended aromatic conjugation of the N^N-donor ligands in the complexes was demonstrated on their binding propensities with CT-DNA and bovine serum albumin (BSA). Both DNA intercalation and groove binding are evidenced, while tryptophan (Trp) and tyrosine (Tyr) binding preferences are revealed from the synchronous fluorescence spectral (SFS) of BSA. The cytotoxic profiling of the complexes performed on hepatocellular carcinoma cells (HepG2) in the dark and in the presence of green light indicated their dose-dependent cytotoxicity. The [Ru II (N^N)2(ox)] complexes exhibit enhanced photocytotoxicity mediated by efficient generation of cytotoxic 1 O 2 and DNA interaction. All the complexes internalize to the HepG2 liver cancer cells efficiently and localize to the cytoplasm and nucleus. The complexes exhibited potent anti-proliferative, anti-clonogenic, and anti-migratory effects on the cancer cells, suggesting their potential promise for therapeutic applications.

chemistry, inorganic & nuclear
Impact of Mitochondrion-Targeting Group on the Reactivity and Cytostatic Pathway of Platinum(IV) Complexes.

Suxing Jin,Yigang Hao,Zhenzhu Zhu,Nafees Muhammad,Zhenqin Zhang,Kun Wang,Yan Guo,Zijian Guo,Xiaoyong Wang

DOI: https://doi.org/10.1021/acs.inorgchem.8b01707

IF: 4.6

2018-01-01

Inorganic Chemistry

Abstract:Platinum(IV) complexes are prodrugs of cisplatin with multiple potential advantages over platinum(II) drugs. Mitochondria play pivotal roles in producing energy and inducing death of cancer cells. Two platinum(IV) complexes, namely, c,c,t-[Pt(NH3)2Cl2(OH)(OCOCH2CH2CH2CH2PPh3)]Br and c,c,t-[Pt(NH3)2Cl2(OCOCH2CH2CH2CH2PPh3)2]Br2, were designed to explore the effect of mitochondrion-targeting group(s) on the bioactivity and cytotoxicity of platinum(IV) complexes. The complexes were characterized by electrospray ionization mass spectrometry, reverse-phase high-performance liquid chromatography, and multinuclear (1H, 13C, 31P, and 195Pt) NMR spectroscopy. The introduction of triphenylphosphonium targeting group(s) markedly influences the reactivity and cytotoxicity of the Pt(IV) complexes. The targeted complex displays more potent disruptive effect on mitochondria but less inhibitory effect on cancer cells than cisplatin. The lipophilicity of the Pt(IV) complexes is enhanced by the targeting group(s), while their reactivity to DNA is decreased. As a result, the mitochondrial morphology and adenosine triphosphate producing ability are impaired, which constitutes an alternative pathway to inhibit cancer cells. This study shows that both the reactivity of platinum(IV) center and the property of axial targeting ligand exert influences on the cytotoxicity of targeted Pt(IV) complexes. For targeting groups with pharmacological activities, their intrinsic function could enrich the anticancer mechanism of Pt(IV) complexes.

Eye-position signals in successive saccades

Ruthenium(II) Complexes with 2-Phenylimidazo[4,5-f][1,10]phenanthroline Derivatives that Strongly Combat Cisplatin-Resistant Tumor Cells

Ruthenium(II) complexes as mitochondrial inhibitors of topoisomerase induced A549 cell apoptosis

Increasing the cytotoxicity of Ru(II) polypyridyl complexes by tuning the electron donating ability of 1,10-phenanthroline ligands

Systematic evaluation of the antitumor activity of three ruthenium polypyridyl complexes

Homo and heterometallic ruthenium and platinum complexes with multiple targets for therapeutic applications: a review

Antitumor studies evaluation of triphenylphosphine ruthenium complexes with 5,7-dihalo-substituted-8-quinolinoline targeting mitophagy pathways

Exploring the potential of ruthenium(ii)–phosphine–mercapto complexes as new anticancer agents

Photoinduced synergistic cytotoxicity towards cancer cells <i>via</i> Ru(II) complexes

A Comparative Study on Interactions of Cisplatin and Ruthenium Arene Anticancer Complexes with Metallothionein Using MALDI-TOF-MS

Design, synthesis and anticancer evaluation of novel half-sandwich Ru(II) complexes bearing pyrazalone moiety: Apoptosis inducers based on mitochondrial dysfunction and G0/G1 arrest

Cyclometalated Ru(II)-NHC Complexes with Phenanthroline Ligand Induce Apoptosis Mediated by Mitochondria and Endoplasmic Reticulum Stress in Cancer Cells

Frequent activation of c-kis as a transforming gene in fibrosarcomas induced by methylcholanthrene.

The ruthenium complex assists in nuclear targeting and selective killing of tumor cells

Multi-targeted organometallic ruthenium(II)-arene anticancer complexes bearing inhibitors of poly(ADP-ribose) polymerase-1: A strategy to improve cytotoxicity.

Ru(ii) polypyridyl complex-incorporated and folate-conjugated vehicle for cancer cell imaging and photoinduced inactivation.

Biotin-conjugated Ru(II) complexes with AIE characteristics as mitochondria-targeted photosensitizers for enhancing photodynamic therapy by disrupting cellular redox balance

Ruthenium Complexes as Promising Candidates against Lung Cancer

A lysosome-targeted ruthenium(II) polypyridyl complex as photodynamic anticancer agent

Photocytotoxic Kinetically Stable Ruthenium(II)-N,N-donor Polypyridyl Complexes of Oxalate for Anticancer Activity Against HepG2 Liver Cancer Cells

Impact of Mitochondrion-Targeting Group on the Reactivity and Cytostatic Pathway of Platinum(IV) Complexes.